Investors

Press Releases

All Releases

View Summary Two-Year Results From Phase 3 VISTA Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Feb 10, 2014
PDF 21.4 KB Add to Briefcase
View Summary Regeneron to Report Fourth Quarter and Full Year 2013 Financial and Operating Results and Host Conference Call and Webcast on February 11, 2014
Jan 21, 2014
PDF 8.6 KB Add to Briefcase
View Summary Regeneron and Bayer to Develop New Treatment Option for Wet Age-Related Macular Degeneration
Jan 13, 2014
PDF 14.8 KB Add to Briefcase
View Summary Regeneron Launches New Human Genetics Initiative
Jan 13, 2014
PDF 13.4 KB Add to Briefcase
View Summary Regeneron and Geisinger Health System Announce Major Human Genetics Research Collaboration
Jan 13, 2014
PDF 16.7 KB Add to Briefcase
View Summary Regeneron Announces Amendment to Investor Agreement with Sanofi
Jan 13, 2014
PDF 11.5 KB Add to Briefcase
View Summary Sanofi and Regeneron Announce Collaboration with American College of Cardiology for PCSK9 Inhibitor Clinical Program
Dec 19, 2013
PDF 18.4 KB Add to Briefcase
View Summary Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication
Dec 18, 2013
PDF 18.5 KB Add to Briefcase
View Summary Regeneron Announces Presentation at the 32nd Annual J. P. Morgan Healthcare Conference
Dec 17, 2013
PDF 8.3 KB Add to Briefcase
View Summary Regeneron Announces Upcoming 2013 Investor Conference Presentation
Dec 4, 2013
PDF 8.3 KB Add to Briefcase
View Summary Sanofi and Regeneron's Dupilumab Named "Clinical Advance of the Year" by Scrip Intelligence
Nov 25, 2013
PDF 15.5 KB Add to Briefcase
View Summary Regeneron's Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
Nov 25, 2013
PDF 12.0 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan
Nov 22, 2013
PDF 18.2 KB Add to Briefcase
View Summary Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Nov 22, 2013
PDF 18.8 KB Add to Briefcase
View Summary Regeneron Highlights EYLEA® (aflibercept) Injection Data to Be Presented at American Academy of Ophthalmology Annual Meeting
Nov 12, 2013
PDF 21.5 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Diabetic Macular Edema
Nov 7, 2013
PDF 22.1 KB Add to Briefcase
View Summary Regeneron Reports Third Quarter 2013 Financial and Operating Results
Nov 5, 2013
PDF 36.2 KB Add to Briefcase
View Summary Regeneron Announces Upcoming 2013 Investor Conference Presentations
Nov 1, 2013
PDF 11.5 KB Add to Briefcase
View Summary Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
Oct 24, 2013
PDF 10.7 KB Add to Briefcase
View Summary Regeneron Reports Positive Phase 3 Data for EYLEA® (aflibercept) Injection in Macular Edema Following Branch Retinal Vein Occlusion
Oct 21, 2013
PDF 18.3 KB Add to Briefcase
Showing 21-40 of 226 Page: 1 2 3 4 5 6 ... 12  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase


Close
Form content here please :)